Clinical Trials Logo

Vasomotor Symptoms (VMS) clinical trials

View clinical trials related to Vasomotor Symptoms (VMS).

Filter by:
  • None
  • Page 1

NCT ID: NCT04080297 Completed - Clinical trials for Vasomotor Symptoms (VMS)

Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen

Start date: January 10, 2014
Phase: Phase 1
Study type: Interventional

Open-label, two dose study of Q-122, over a 4 week treatment period to explore the effects of Q-122 in a population of women with a history of breast cancer taking an aromatase inhibitor or tamoxifen.

NCT ID: NCT03541200 Completed - Clinical trials for Vasomotor Symptoms (VMS)

Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

Start date: April 18, 2018
Phase: Phase 2
Study type: Interventional

An open-label, long term extension study of MT-8554 in postmenopausal women experiencing moderate to severe vasomotor symptoms who completed Study MT-8554-A01

NCT ID: NCT03518138 Completed - Clinical trials for Vasomotor Symptoms (VMS)

Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

Start date: October 24, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2 proof-of-concept (POC) study designed to determine the effectiveness of Q-122 for the treatment of Vasomotor Symptoms (VMS) versus placebo. Participants who meet all eligibility criteria following the Screening/Run-In period will be randomized to 1 of 2 treatment arms; blinded Q-122 or placebo for a period of 28 days. All participants will be followed for a 2-week, drug-free, follow-up period after their last dose of blinded Q-122/placebo before termination from the study.

NCT ID: NCT02049164 Terminated - Clinical trials for Vasomotor Symptoms (VMS)

Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)

Start date: January 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effective dose or dose range of AR08 in the treatment of VMS in menopausal females.